CSIMarket
 


Igm Biosciences Inc   (IGMS)
Other Ticker:  
 
 

IGMS's Capital Expenditures Growth by Quarter and Year

Igm Biosciences Inc 's Capital Expenditures results by quarter and year




IGMS Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2.70 1.76 6.71
III Quarter September 3.08 2.71 2.25 6.57
II Quarter June 3.91 1.82 3.16 2.52
I Quarter March 3.94 2.98 6.07 1.71
FY   10.93 10.21 13.24 17.51



IGMS Capital Expenditures third quarter 2023 Y/Y Growth Comment
Igm Biosciences Inc reported Capital Expenditures increase of 13.76% year on year in the third quarter 2023, to $ 3.08 millions, this is lower than Igm Biosciences Inc 's recent average Capital Expenditures surge of 169.23%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Capital Expenditures growth. While Igm Biosciences Inc ' s Capital Expenditures growth of 13.76% ranks overall at the positon no. 1103 in the third quarter 2023.




IGMS Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 53.41 % -73.77 % 1018.33 %
III Quarter September 13.76 % 20.44 % -65.75 % 277.59 %
II Quarter June 114.84 % -42.41 % 25.4 % -
I Quarter March 32.21 % -50.91 % 254.97 % -
FY   - -22.89 % -24.39 % 648.29 %

Financial Statements
Igm Biosciences Inc 's third quarter 2023 Capital Expenditures $ 3.08 millions IGMS's Income Statement
Igm Biosciences Inc 's third quarter 2022 Capital Expenditures $ 2.71 millions Quarterly IGMS's Income Statement
New: More IGMS's historic Capital Expenditures Growth >>


IGMS Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -0.37 % -21.78 % 2.13 %
III Quarter September -21.15 % 48.9 % -28.8 % 160.71 %
II Quarter June -0.76 % -38.93 % -47.94 % 47.37 %
I Quarter March 45.93 % 69.32 % -9.54 % 185 %
FY (Year on Year)   - -22.89 % -24.39 % 648.29 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #152
Overall #1103

Capital Expenditures Y/Y Growth Statistics
High Average Low
1182.7 % 169.23 % -60.86 %
(Mar 31 2021)   (Jun 30 2022)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #152
Overall #1103
Capital Expenditures Y/Y Growth Statistics
High Average Low
1182.7 % 169.23 % -60.86 %
(Mar 31 2021)   (Jun 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Igm Biosciences Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
184.17 % 20.23 % -65.46 %
(Mar 31 2020)  


IGMS's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Igm Biosciences Inc disclosed fall in Capital Expenditures from the second quarter by -21.15% to $ 3.08 millions, from $ 3.91 millions released in the previous quarter.

Even seasonal circumstance have not rescue the III. Quarter for the Igm Biosciences Inc , Cristina Gonçalves, a business consultant allocated in Porto said, she identified further challenges down the road for Igm Biosciences Inc and mentioned that average sequential Capital Expenditures growth is at 20.23% for Igm Biosciences Inc .

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Igm Biosciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2043.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #317
Overall #2043
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #317
Overall #2043
Capital Expenditures Q/Q Growth Statistics
High Average Low
184.17 % 20.23 % -65.46 %
(Mar 31 2020)  


IGMS's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Igm Biosciences Inc realized fall in Capital Expenditures sequentially by -21.15% to $ 3.08 millions, from $ 3.91 millions declared in the previous quarter.

Some cyclical factors could not recover the III. Quarter for the Igm Biosciences Inc , Cristina Gonçalves, a business consultant allocated in Porto wrote, she mentioned certan skepticism conserning Igm Biosciences Inc 's direction.

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Igm Biosciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2043.


Igm Biosciences Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 13.63 $ 13.26 $ 11.17 $ 10.21 $ 9.27
Y / Y Capital Expenditures Growth (TTM) 46.95 % 50.48 % 10.03 % -22.94 % -49.01 %
Year on Year Capital Expenditures Growth Overall Ranking # 1868 # 778 # 1672 # 1967 # 2248
Seqeuential Capital Expenditures Change (TTM) 2.81 % 18.72 % 9.41 % 10.05 % 5.28 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1265 # 627 # 1535 # 2002 # 1306




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Igm Biosciences Inc 's cumulative twelve months Capital Expenditures were $ 14 millions, company would post below average annual Capital Expenditures growth of 5.28% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Igm Biosciences Inc 's Capital Expenditures growth from the 3.91% growth in Jun 30 2023.

In the Healthcare sector 277 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 778 to 1868.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1182.7 %
169.23 %
-60.86 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 278
Overall # 1868

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1182.7 %
169.23 %
-60.86 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 171
S&P 500 # 1265
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Igm Biosciences Inc 's cumulative twelve months Capital Expenditures were $ 14 millions, company would post below average annual Capital Expenditures growth of -60.86% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Igm Biosciences Inc 's Capital Expenditures growth from the 3.91% growth in Jun 30 2023.

In the Healthcare sector 277 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 778 to 1868.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1182.7 %
169.23 %
-60.86 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 278
Overall # 1868

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1182.7 %
169.23 %
-60.86 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 171
S&P 500 # 1265




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
IGMS's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for IGMS's Competitors
Capital Expenditures Growth for Igm Biosciences Inc 's Suppliers
Capital Expenditures Growth for IGMS's Customers

You may also want to know
IGMS's Annual Growth Rates IGMS's Profitability Ratios IGMS's Asset Turnover Ratio IGMS's Dividend Growth
IGMS's Roe IGMS's Valuation Ratios IGMS's Financial Strength Ratios IGMS's Dividend Payout Ratio
IGMS's Roa IGMS's Inventory Turnover Ratio IGMS's Growth Rates IGMS's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Axonics Inc 23.88%$ 23.884 millions
Universal Health Services Inc 23.77%$ 23.768 millions
Abbvie inc 23.73%$ 23.729 millions
Regeneron Pharmaceuticals Inc 23.51%$ 23.509 millions
Prestige Consumer Healthcare Inc 23.48%$ 23.485 millions
Medpace Holdings Inc 21.23%$ 21.229 millions
Cytek Biosciences Inc 21.13%$ 21.130 millions
Brookdale Senior Living Inc 20.76%$ 20.763 millions
Prophase Labs Inc 20.58%$ 20.578 millions
Castle Biosciences Inc 20.46%$ 20.461 millions
Ufp Technologies Inc 20.27%$ 20.268 millions
Healthcare Services Group Inc 20.10%$ 20.102 millions
Abbott Laboratories19.91%$ 19.914 millions
Select Medical Holdings Corp19.68%$ 19.684 millions
Option Care Health Inc 19.43%$ 19.430 millions
Monte Rosa Therapeutics Inc 18.50%$ 18.500 millions
Exelixis Inc 16.54%$ 16.536 millions
Viemed Healthcare Inc 16.44%$ 16.439 millions
Dentsply Sirona Inc 15.63%$ 15.625 millions
Cns Pharmaceuticals Inc 15.19%$ 15.192 millions
Igm Biosciences Inc 13.72%$ 13.722 millions
Rxsight Inc 12.59%$ 12.586 millions
Privia Health Group Inc 12.50%$ 12.500 millions
Geron Corp12.28%$ 12.281 millions
National Research Corporation12.23%$ 12.227 millions
Ptc Therapeutics inc 12.22%$ 12.223 millions
Sight Sciences Inc 11.76%$ 11.765 millions
Mersana Therapeutics Inc 10.80%$ 10.798 millions
Warby Parker Inc 9.87%$ 9.867 millions
Immunovant Inc 9.68%$ 9.677 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com